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Abstract: (1) Background: Low back pain (LBP) is often associated with intervertebral disc degener-
ation (IVDD). Autochthonous progenitor cells isolated from the center, i.e., the nucleus pulposus,
of the IVD (so-called nucleus pulposus progenitor cells (NPPCs)) could be a future cell source for
therapy. The NPPCs were also identified to be positive for the angiopoietin-1 receptor (Tie2). Similar
to hematopoietic stem cells, Tie2 might be involved in peroxisome proliferator-activated receptor
delta (PPARδ) agonist-induced self-renewal regulation. The purpose of this study was to investigate
whether a PPARδ agonist (GW501516) increases the Tie2+ NPPCs’ yield within the heterogeneous
nucleus pulposus cell (NPC) population. (2) Methods: Primary NPCs were treated with 10 µM of
GW501516 for eight days. Mitochondrial mass was determined by microscopy, using mitotracker
red dye, and the relative gene expression was quantified by qPCR, using extracellular matrix and
mitophagy-related genes. (3) The NPC’s group treated with the PPARδ agonist showed a significant
increase of the Tie2+ NPCs yield from ~7% in passage 1 to ~50% in passage two, compared to the
NPCs vehicle-treated group. Furthermore, no significant differences were found among treatment
and control, using qPCR and mitotracker deep red. (4) Conclusion: PPARδ agonist could help to
increase the Tie2+ NPCs yield during NPC expansion.
Keywords: tissue-specific progenitor cells; angiopoietin-1 receptor; intervertebral disc; lower back
pain; intervertebral disc degeneration; PPARδ agonist
1. Introduction
1.1. Nucleus Pulposus Cells and Their Progenitors
Nucleus pulposus (NP) tissue is located in the center of the intervertebral disc (IVD).
NP tissue is in charge of the distribution of the loading compression forces in collaboration
with the annulus fibrosus (AF) tissue [1]. It has been demonstrated that NP is derived
from the notochord [2–4]. The notochordal cells are presented with chondrocyte-like
“nucleopulpocytes” (nucleus pulposus cells (NPCs)) in early life and are progressively lost
in adults [5,6]. The notochordal cells maintain homeostasis by stimulating the synthesis
of extracellular matrix (ECM) [7]. The disappearance of notochordal cells with aging was
often speculated to reflect a possible reason for intervertebral disc degeneration (IVDD) [7].
The NP progenitor cell (NPPC) from NP tissue might be the successor of notochordal
cells to maintain homeostasis in NP tissue [8–10]. The main characteristics of these NPPCs
are their self-renewal ability, their capability to form Colony-Forming Unit-spheroids
(CFU-s) in semi-solid media, and their positivity for cell surface marker Angiopoietin
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receptor-1 (aka Tie2) [8–10]. The NPPCs (Tie2+ NPCs) are multipotential, but not the fully
differentiated NPCs (Tie2-NPCs) [8–10]. Besides the absence of Tie2, differentiated NPCs
can be distinguished from multipotent NPPCs by their lower clonogenic ability [8–10].
The adult multipotent stem cells play an important role in degenerative diseases.
It could be a possibility that the shortage of these tissue-specific stem cells, especially
in elderly people, is a main reason for tissue degeneration and malfunction [11]. The
nervous system degeneration was considered irreversible. However, adult progenitor
cells proved this paradigm wrong [12]. In the IVD, although NPPCs are indeed present in
adults, this cell population decreases drastically with increasing age (>40 years) [13–15].
The recovery of NPPCs’ yield of the whole NPC population might be a possible way
to reverse or at least slow down the process of IVDD. Therefore, new protocols for (i)
how to maintain the number of initially cell-sorted NPPCs in cell culture and (ii) the
protection of their stemness are urgently warranted. Recent work could clearly demonstrate
that changing the expansion protocol from 2D to 3D can indeed increase the Tie2+ cell’s
yield [16,17]. Moreover, NPPC protection through molecular injection could rebuild the
cell’s homeostasis in IVDD; it could evolve as a new approach for IVDD therapy. A similar
example is that, after spinal cord injury, the endogenous neural stem cells could help rebuild
the spinal cord function [18]. A recent study by Wangler et al. (2019) could demonstrate
that there is even a link between increased homing of mesenchymal stromal cells (MSCs)
and an increase of the Tie2+ cell’s fraction inside the native cell population of the IVD;
this has been shown in both bovine and human organ culture models, respectively. This
connection unveals a possible additional value of MSCs cell therapy and seems to be a way
to indirectly stimulate the proliferation of the Tie2+ fraction [19]. This observation certainly
needs a closer investigation in the future.
Since the NPPCs are rare in the NP tissues, and as these cells do not seem to proliferate
well, in vitro experiments are quite limited. The purified NPPCs are losing their phenotype
on a monolayer culture only after 10 days [9]. However, the NPPC percentage in the whole
NPC population expansion is relatively stable for 28 days [8]. To get enough NPPC for
further research, it is important to increase the NPPC (Tie2+ NPCs) yield during NPC
expansion. Another approach for IVDD therapy would be to increase the endogenous
NPPC yield in vivo.
1.2. Tie2 and Self-Renewal
Hematopoietic stem cells (i.e., CD34+) are positive for the Tie2 marker and share
many features with NPPCs, such as a fondness for a hypoxic environment and their origin
from the mesoderm [20]. Recent evidence suggests that the PPARδ agonist could induce
mitophagy and increase the self-renewal of Tie2+ hematopoietic stem cells but not Tie2-
cells [20]. Mitophagy is the selective degradation of mitochondria by autophagy, and it
often occurs in defective mitochondria, after damage or stress [21]. Recently, Ito et al.
investigated the mitophagy pathway by treating the Tie2+ hematopoietic stem cells with
the PPARδ agonist GW501516 and L-165041 [20]. The PPARδ is one of the main classes of
peroxisome proliferator-activated receptor (PPAR); the activity of PPARδ can change the
body’s fuel preference from glucose to lipids [13] and was formerly used in athletes as a
doping substance, to increase their performance. Furthermore, the PPARδ agonist induces
mitochondrial clearance and hence mediates the self-renewal capacity of hematopoietic
cells [20]. This process could be inhibited by knockdown proteins of PARKIN (which is the
product of the PARK2 gene) or PTEN-induced putative kinase 1 (which is the product of
the PINK1 gene). The proteins PARKIN and PINK1 are two key players in the progress
of mitophagy [20]. Moreover, with Tie2+ hematopoietic stem cells, PPARδ agonist can
up-regulate the gene expression of PINK1 and PARK2. The upregulation of the PINK1
gene was through the upregulation of FOXO3 gene. Upregulation of these genes lead
to an increase mitophagy. This mechanism enables self-renewal in Tie2 + hematopoietic
stem cells to be increased by PPARδ agonists. Additionally, hematopoietic Tie2 + stem
cells lose their ability to renew themselves when they prevent the mitophagy through
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the inhibition of the PINK1 and PARK2 proteins. On the contrary, this “self-renewal path
of PPARδ agonist mitophagy” could not be demonstrated for hematopoietic Tie2- stem
cells [20]. Furthermore, mitophagy induces stem cell behavior by a complex regulation of
metabolism, calcium, and reactive oxygen species (ROS) [22].
1.3. Mitophagy in NPC
In this context, mitophagy-related gene and protein expression of PARKIN and
PINK1 [23] showed a difference between healthy and disordered NPCs [24–26]. Accord-
ingly, the lower gene expression level of PARK2 has been associated with disc-related
disorders, and methylation of the PARK2 promoter may influence the degeneration of the
IVD [14,15]. In line with this, an increase of mitophagy has recently been associated with
aging in rats [24]. Some studies showed that cyclosporine A (CSA) and a knockdown of
PARKIN eliminated the apoptosis protection by salidroside and melatonin, and increased
the senescence of NPCs [25,26].
1.4. Hypothesis and Aims
We hypothesized that the PPARδ agonist GW501516 will increase the self-renewal
ability of Tie2+ NPCs by the stimulation of the mitophagy pathway. In this study, the major
aim was to investigate whether the addition of GW501516 to the basal culture medium
would increase the Tie2+ NPPC’ yield of NPC (i.e., defined as the percentage of Tie2 + cells).
The second major aim was to investigate whether this process was regulated by mitophagy,
analyzed by relative expression of mitophagy-related genes and mitochondrial mass.
2. Materials and Methods
2.1. NPC Isolation and Culture
In this study, human NP tissues were obtained from eight patients with traumatic spine
injuries (Pfirrmann gradings 1 and 2) who provided written consent and ethical approval
from the local ethical committee (Reference # 2019-00097) (Table 1). After dissection of
the NP tissue, it was washed twice with phosphate-buffered saline (PBS), to remove any
kind of contamination from non-NP tissue cells that can occur during injury and surgery.
NP cells were isolated as follows. A two-step digestion protocol was performed with
1.9 mg/mL pronase (Roche, Basel, Switzerland), for one hour, and 65 U/mL collagenase
type II (Worthington, London, UK), overnight. The debris was cleared by filtration through
a 100 µm cell strainer (Falcon; Becton & Dickinson, Allschwil, Switzerland). Cell numbers
and viability were then assessed by using a Neubauer-improved chamber with trypan
blue to stain dead cells. The primary NPCs at Passage zero (P0) were seeded on T150
or T300 flasks from TPP™ (cat# 90151 T150, cat# 90301 T300 Trasadingen, Switzerland)
at a density of ~700–10,000 cells/cm2 (based on the number of cells harvested) within a
basal culture media. The basal media consisted of low glucose Dulbecco’s Modified Eagle
Medium (LG-DMEM) media (cat# 11885084 Gibco, Life Technologies, Zug, Switzerland)
supplemented with 10% FCS (cat# F7524, Sigma-Aldrich, Buchs, Switzerland) and 1%
Penicillin/Streptomycin/Glutamine (P/S/G) (cat# 10378016 Gibco). These P0 NPCs were
then cultured until they reached 90% confluency in normoxia. Then, NPCs were detached
with Trypsin-EDTA (1X) for 5 min. The cells were then resuspended in basal culture
media medium supplemented with 10% dimethyl sulfoxide (DMSO). The NPCs were then
frozen at −80 ◦C, using a freezing container (“Mr. Frosty freezing container” cat# 51000001;
Thermo Fisher Scientific), and left for two days. Finally, the cells were transferred to
−150 ◦C, for a long time storage.
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Table 1. Donor list with gender, age, Pfirrmann grade, tissue weight, and the number of
isolated cells.
No. Gender Age PfirrmannGrade * Location
1 female 37 1 T12/L1
2 female 39 2 L2/L3
3 male 40 2 L2/L3
4 male 19 1 T12/L1
5 male 28 1 L4/L5
6 male 38 2 L4/5
7 male 23 1-2 T11/12
8 male 40 2 T11/T1
* The grading was performed by two spine surgeons, i.e., Christoph E. Albers and Sonja Häckel. Figure 2 (donors
1, 2, and 6), Figures 3 and 5 (donors 3, 4, 5, 6, and 8), and Figure 4 (donors 3, 4, 5, and 7).
2.2. PPARδ Agonist Treatment
At P3, PPARδ agonist treatment media included the basal culture media with 0.1 µM
of GW501516 (cat# SML1491, Sigma, Buchs, Switzerland dissolved in Dimethyl sulfoxide
(DMSO)) and supplemented with 2.5 ng/mL fibroblast growth factor-2 (FGF-2) (Peprotech,
London, UK), to better maintain the progenitor phenotype [9,27]. The concentration of
GW501516 used in our study refers to the research published by Ito et al. [20]. In the
control medium, the GW501516 was replaced by DMSO vehicle (0.01% in volume). For
our experiments, 100,000 cells were seeded in T75 flasks (Figure 1). All cells were cultured
until 80% confluency (which corresponded to ~eight days of culture).
Figure 1. Schematic representation of the study experimental design; P = passage.
2.3. Visualisation of Cell’s Morphology
Cells’ morphology was quantified by using ImageJ v1.53c software on the microscopic
pictures, using “cell body circularity” functionality [28,29]. An example of how the cells’
outlines were defined by manual segmentation can be found in a previous study [17].
2.4. Flow Cytometry
The cells were cultured for about eight days, based on the confluence. Then, the cells
were trypsinized, using 0.25% Trypsin-EDTA solution, for 5 min, as recommended by the
manufacturers. To assess the Tie2+ NPPC yield, the NPCs were stained with the Tie2-PE
antibody (1:20) (cat# FAB3131P, R&D Systems, Muttenz, Switzerland), for 20 min, at 4 ◦C,
and dead cells were stained with 4′,6-diamidino-2-phenylindole (DAPI) (0.1 µg/mL).
To assess the mitophagy mass of Tie2+ NPCs and Tie2- NPCs, the cells were stained
with 0.5 µM of MitoTracker™ Deep Red FM (cat# M22426, Thermo Fisher Scientific Inc.,
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Basel, Switzerland), for 30 min, at 37 ◦C. The cell cycle was assessed by Vybrant™ Dye-
Cycle™ Violet Stain (10 µM) (cat#V35003, Thermo Fisher Scientific, Basel, Switzerland),
which was incubated for 30 min, at 37 ◦C. Before the Tie2 stain, MitoTracker™ Deep Red
FM and Vybrant™ DyeCycle™ Violet were applied as a single mix. Then, Tie2+ NPCs
were stained with the Tie2-PE antibody (1:20) (cat# FAB3131P R&D Systems, Muttenz,
Switzerland), for 20 min, at 4 ◦C. This staining protocol was strictly followed according to
the manufacturer’s instructions. The flow cytometer (CytoFLEX S 5350, Indiana, United
States) was used to analyze and quantify the Tie2+ NPC yield and mitochondria mass. The
flow cytometric data were analyzed with FlowJo software, version 10.4.2, for Mac OS X
(Treestar, Ashland, OR, USA).
2.5. qPCR
The expression of the mitophagy-related genes Parkin RBR E3 Ubiquitin Protein Ligase
(PARK2), phosphatase and tensin homolog deleted on chromosome ten (PTEN)-induced
putative kinase 1 (PINK1), Forkhead Box O3 (FOXO3), silent mating type information
regulation 2 homolog 1 (SIRT1), silent mating type information regulation 2 homolog
1 (SIRT3), and peroxisome proliferator-activated receptor delta (PPARD) were analyzed.
Likewise, the expression of the “nucleopulpocytic”-phenotype-related genes Aggrecan
(ACAN), Collagen type I (COL1), Collagen type II (COL2), and Keratin 19 (KRT19), as well
as angiopoietin-1 receptor (Tie2) (TEK), were assessed [8,30].
Total RNA was extracted with the GenElute™ Mammalian total RNA purification kit,
including DNA digestion (cat# RNB100 Sigma-Aldrich, Buchs, Switzerland). The RNA was
reverse-transcribed into cDNA, using the high-capacity cDNA Kit (cat# 4368814, Thermo
Fisher). The primer sequences used are listed in Table 2. The qPCR was performed in
duplicates (CFX96 Touch, Bio-Rad) with mixed cDNA and (250 nM) forward and reverse
primers (Microsynth, Switzerland) in iTaq™ universal SYBR® Green Supermix (Bio-Rad).
Relative expression was computed, using the 2−∆∆Cq method, with two reference genes, i.e.,
18S ribosomal RNA gene (18S) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
respectively. The 2−∆∆Cq method was calculated with Microsoft Excel (Microsoft 356 MSO,
Microsoft, Redmond, USA). The data were normalized to the control group.
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Table 2. Primers list.
Name Description Primer Forward Primer Reverse
18S Ribosomal 18s RNA gene CGA TGC GGC GGC GTT ATT C TCT GTC AAT CCT GTC CGT GTC C
GAPDH Glyceraldehyde-3-phosphate dehydrogenase ATC TTC CAG GAG CGA GAT GGA GGC ATT GCT GAT GAT
ACAN Aggrecan core protein CAT CAC TGC AGC TGT CAC AGC AGC ACT ACC TCC TTC
COL1 Collagen type 1 GTG GCA GTG ATG GAA GTG CAC CAG TAA GGC CGT TTG
COL2 Collagen type 2 AGC AGC AAG AGC AAG GAG AA GTA GGA AGG TCA TCT GGA
KRT19 Keratin 19 TGT GTC CTC GTC CTC CTC GCG GAT CTT CAC CTC TAG C
TEK TEK receptor tyrosine kinase TTA GCC AGC TTA GTT CTC TGT GG AGC ATC AGA TAC AAG AGG TAG GG
PARK2 Parkin RBR E3 Ubiquitin Protein Ligase GTC TTT GTC AGG TTC AAC TCC A GAA AAT CAC ACG CAA CTG GTC
PINK1 Phosphatase and tensin homolog deleted onchromosome ten (PTEN)-induced putative kinase 1 CTCCAGCGAAGCCATCTT TCTGTAAGTGACTGCTCCATAC
PPARD Peroxisome proliferator-activated receptor delta CAG GGC TGA CTG CAA ACG A CTG CCA CAA TGT CTC GAT GTC
SIRT1 Silent mating type information regulation 2 homolog 1 TAGCCTTGTCAGATAAGGAAGGA ACAGCTTCACAGTCAACTTTGT
SIRT3 Silent mating type information regulation 2 homolog 3 CAG CAA CCT CCA GCA GTA CGT GTA GAG CCG CAG AAG
FOXO3 Forkhead Box O3 CGG ACA AAC GGC TCA CTC T GGA CCC GCA TGA ATC GAC TAT
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2.6. Population Doubling Level (PDL)
The population growth was estimated by the cumulative population doubling level







where N0 = initially seeded cell number and Nt = cell number at time point, t.
2.7. Statistics
Statistical analysis was performed, using Prism 7.0d for Mac OS X (GraphPad, La Jolla,
California, US). A Shapiro–Wilk test was performed on all data prior to analysis, to check
for normal distribution. Nonparametric distribution was assumed. As a consequence,
statistical significance was determined, using the Mann–Whitney U test and Kruskal–Wallis
(K–W) signed-rank test, followed by a Dunn’s multiple comparison test (for three or four
groups). Values are given as means ± SD. A p-value <0.05 was considered to be significant.
3. Results
3.1. PPARδ Agonist Treatment Changed the Morphology of NPCs
We thawed the NPCs and seeded the cells with and without PPARδ agonist treatment
(Figure 2). After seven days, we compared the morphology of NPCs from the PPARδ
agonist treatment group (Figure 2a) and the control group (Figure 2b). Under the light
microscope (10x), there were, at first, no obvious differences in morphology. However,
quantification of cell circularity (Figure 2c) revealed that PPARδ agonist treatment resulted
in overall more rounded cell shapes, as compared to cells cultured within the control group.
Figure 2. Light microscopy phase-contrast pictures of nucleus pulposus cells (NPCs) growth with
PPARδ agonist treatment (a) and control (b). Here, “Control” represents cells cultured within control
media without PPARδ agonist, “PPARδ” refers to cells cultured with PPARδ agonist treatment. Scale
bar = 100 µm. The measure using ImageJ showed the cells’circularity (c). Each dot represents one
cell (n = 100), taken from three donors marked in red, green, and blue for both groups, respec-
tively. Mann–Whitney U test p = 0.01 * = p-value < 0.05. Lines in (c) represent means ± standard
deviation (SD).
3.2. PPARδ Agonist Treatment Increased the Tie2+ NPC Yield of NPCs
The Tie2+ yield of the NPCs population at day 0 was 7.1 ± 9.6% (mean ± SD).
The Tie2+ yield of PPARδ agonist treated and vehicle control group was 48.9 ± 12.8%
(mean ± SD) and 30 ± 19.4% (mean ± SD), respectively (Figure 3a). After about eight days
of culture, both passage two NPCs from the PPARδ-agonist-treated group (significantly,
p = 0.01) and vehicle control group (p = 0.231) increased the Tie2+ NPC yield, compared
with day 0. The Tie2+ yield between the PPARδ-agonist-treated group, and the vehicle
group was not statistically different (p = 0.773).
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The population doubling level (PDL) was assessed as an indicator for proliferation
(Figure 3b). We compared the PDL of Tie2+ NPCs and the Tie2- NPCs of PPARδ-agonist-
treated group and vehicle group. Only the PPARδ-agonist-treated group between Tie2+
and Tie2- presented a significant difference (p = 0.033). With PPARδ-agonist treatment, the
Tie2+ NPCs had a significant higher PDL of 9.3 ± 2.5 (mean ± SD), compared with Tie2-
NPCs with 5.5 ± 0.8 (mean ± SD).
3.3. Correlation between mRNA Expression and PPARδ Agonist Treatment
We compared the relative gene expression between NPCs with PPARδ-agonist treat-
ment and vehicle control (assigned to 1.0) (Figure 4). Overall, there were no signifi-
cant differences in relative gene expression between these two groups. The PPARδ-
agonist treatment did not change significantly the ECM-relevant, mitophagy-relevant,
and “nucleopulpocytic”–relevant relative gene expression.
Figure 4. Relative gene expression of primary NPCs after PPARδ agonist exposure after eight days
of culture normalized to vehicle (DMSO) control (assigned to 1.0). ACAN stands for aggrecan,
COL1 represents collagen type I, COL2 stands for collagen type II, FOXO3 stands for Forkhead
Box O3, PARK2 stands for Parkin RBR E3 Ubiquitin Protein Ligase, PINK1 stands for Phosphatase
and tensin homolog deleted on chromosome ten (PTEN)-induced putative kinase 1, PPARD stands
for peroxisome proliferator-activated receptor delta, SIRT1 stands for silent mating type informa-
tion regulation 2 homolog 1, SIRT3 stands for silent mating type information regulation 2 ho-
molog 3, TEK stands for TEK receptor tyrosine kinase (Tie2), and KRT19 stands for Keratin 19; “a.u.”
refers to arbitrary units; n = 4 donors, Mann–Whitney U test. Lines represent means ± standard
deviation (SD).
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3.4. Correlation between Mitochondrial Mass and PPARδ Agonist Treatment
To assess if the PPARδ agonist treatment will influence the mitochondria mass which
usually decreases when mitophagy is stimulated, we quantified the mitochondria mass
with mitotracker deep red (Figure 5). The mitochondria mass of Tie2+ NPCs was ex-
pressed relative to the Tie2- NPCs. In more detail, the Tie2+ NPCs with PPARδ agonist
treatment showed a significant decrease in relative mitochondria mass, compared to the
control group.
Figure 5. Plot of individual values and median of fluorescence intensities (MFIs) of mitochondria
mass in Tie2+ NPCs relative to Tie2- NPCs measured, using mitotracker™ deep red and flow
cytometry. “Control” represents cells cultured with control media without PPARδ agonist, “PPARδ”
refers to cells cultured with PPARδ agonist treatment; “a.u.” refers to arbitrary units. Mann–Whitney
U test, p = 0.0079; ** p-value < 0.01. Lines represent means ± SD; n = 5 donors.
4. Discussion
In this study, we compared the Tie2+ fraction among three groups; i.e., in thawed
primary NPCs in P1, in control in P2, and in PPARδ-treated cells in P2. The PPARδ
agonist treatment significantly increased the Tie2+ NPCs’ yield largely in PPARδ (P2) cells,
compared with the P1 cells, whereas this was not the case in the control group (Figure 3).
Unfortunately, the comparison of PPARδ (P2) and vehicle control (P2) did not show any
significant difference after eight days of monolayer culture. We also tested the PPARδ (P1)
versus vehicle control (P1) at day 13 and PPARδ (P1) versus untreated control (P1) at day
15. Overall, the PPARδ-agonist-treated NPCs had a significantly higher Tie2 percentage,
compared to the control (Supplementary Figure S1 and Table S1). Future research should
focus whether prolongued passaging would even reveal a more pronounced effect of
PPARδ agonist treatment. However, over confluence of cells also may decrease cell viability.
Additionally, the circularity of NPCs with PPARδ agonist treatment showed a more “naïve”
morphology, as compared to the control [29].
The increase of Tie2 yield could be due to two reasons. The first one is the proliferation
of Tie2+ NPCs; the other one is the loss of Tie2- NPCs cells. The PPARδ agonist treatment
induced significantly higher proliferation in the Tie2+ NPCs, compared with the Tie2-
NPCs. With the PPARδ agonist treatment, we revealed an increase from ~7% to ~50%
(which translates to ~7 times boost) of Tie2+ NPCs after ~8 days of monolayer culture.
In contradiction to the PDL measurements, the PPARδ agonist treatment induced
significantly lower mitochondrial mass in the Tie2+ NPCs, compared with the Tie2- NPCs.
This mitochondrial mass was most likely regulated by mitochondrial biogenesis and
mitophagy. However, the result of this study could not exclude biogenesis. In the future, the
biogenesis of mitochondria should be further assessed by the inhibition of mitophagy, using
cyclosporine A (CSA) or hydroxychloroquine (HCQ), both inhibitors of mitophagy [31].
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The ECM-, mitophagy-, NPPC-phenotype-, and IVD-phenotype-related relative gene
expressions between the PPARδ agonist treatment and the control group did not show any
significant differences. However, there was a slight trend of increased ACAN, COL1, COL2,
PINK1, and TEK gene expressions, respectively.
Many researchers believe that the mitochondrial mass correlates to the stemness of
cells [32]. In the hematopoietic stem cells, the relative low mitochondria mass related to
high self-renewal ability [33,34]. Our data revealed that, after PPARδ agonist treatment,
the Tie2+ NPCs population showed a decrease of mitochondria mass and an increase of
proliferation, compared with the Tie2- NPCs population. We assumed that, in NPCs, the
low mitochondrial mass also reflects proliferation, as it is the case in hematopoietic stem
cells. However, one detail still needs to be elucidated, whether the low mitotracker deep
red medians of fluorescence intensity (MFI) were due to the ATP-binding cassette (ABC)
transporters. Many kinds of stem cells have nucleus ABC transporters across cellular
membranes, to efflux molecules.
The protective role of mitophagy in NPCs has been demonstrated in several stu-
dies [24–26]. In contrast to earlier findings, recent publications have contributed to a
raising debate as to whether inhibition of mitophagy by cyclosporine A (CSA), a mitophagy
inhibitor, and parkin-shRNA could prevent cell senescence in rats’ NPCs [35]. However,
these studies did not consider the difference between NPPC, i.e., Tie2+ cells, and NPC,
i.e., Tie2- cells. We suppose that mitophagic function is different in NPPC and Tie2- cells.
The mitophagy might have a protective effect or even might decrease senescence, which
might be again dependent on the proportion of NPPC (Tie2+ cells) and Tie2- NPC. Previous
research showed contradictory results [24–26,35]. These differing results in the literature
may potentially be explained by variation of different percentages of NPPCs in these
expeirments.
The aim of our research was to increase the Tie2+ NPCs percentage of the whole NPC
population during expansion. The classic and common culture conditions are based on
2D culture and normoxic environment [13–15]. In this research, we primarily wanted to
compare the impact of chemical treatments on the Tie2+ NPPCs population [16,17]. For this
reason, the cells were cultured within a normoxic environment. However, the comparison
between hypoxia and normoxia could be taken into account for future analyses.
5. Conclusions
• The PPARδ agonist treatment significantly changed the cell’s morphology towards
more rounded cells in 2D culture.
• The PPARδ agonist significantly accelerated cell proliferation in NPPCs, i.e., Tie2+
cells, compared to Tie2- cells, by a factor of ~7.
• The PPARδ agonist increased the Tie2+ yield after ~day eight of monolayer culture.
• The PPARδ agonist significantly decreased the mitochondria mass in NPPCs, i.e., Tie2+
cells, compared to Tie2- cells.
• The PPARδ agonist did not cause any significant changes in mitophagy-related relative
gene expression, such as PARKIN and PINK1, nor in other ECM-related genes.
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AF Annulus fibrosus
bFGF Fibroblast growth factor-basic
CEP Cartilage endplates
CFU Colony-forming unit
CFU-s Spheroid colony-forming unit
CSA Cyclosporine A
DAPI 4′,6-diamidino-2-phenylindole
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LG-DMEM Low-glucose Dulbecco’s Modified Eagle Medium
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MFI Medians of fluorescence intensity
MSC Mesenchymal stromal cell
NP Nucleus pulposus
NPC Nucleus pulposus cell
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